Vir Biotechnology conducted a world-wide search to find the perfect CEO. In the end, the board picked Bayer’s Marianne De Backer.
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial
Vir Biotechnology Shares Rise 14% on Terminated Collaboration with GSK
GSK is walking away from a core piece of its $345 million bet on Vir Biotechnology. The partners have ended their collaboration on anti-influenza antibodies, freeing Vir to “actively” pitch the candidates to other companies while continuing to work with GSK on different respiratory pathogens.
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
Vir Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as CMO
Vir Biotechnology to Report Fourth Quarter 2023 Financial Results
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses